{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-38717708-tirzepatide:v1","objectPathId":"pubmed-pmid-38717708-tirzepatide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-38717708-tirzepatide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-38717708-tirzepatide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-38717708-tirzepatide-v1.md"},"story":{"slug":"pubmed-pmid-38717708-tirzepatide","version":1,"domain":"Literature metadata","dateInSource":"2026-07-12","sourceCheckedAt":"2026-08-10","publishedAt":"2026-08-13","peptideSlugs":["tirzepatide"],"peptides":[{"slug":"tirzepatide","url":"https://peptidescanner.com/peptides/tirzepatide/"}]},"claims":[{"id":"headline","text":"Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective.","sourceIds":["pubmed-observation-pmid-38717708-2026-07-12-52000ff1efbe"]},{"id":"summary","text":"PubMed lists PMID 38717708 in PharmacoEconomics as Journal Article, with publication-date metadata of 2024-05-08 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-38717708-2026-07-12-52000ff1efbe"]},{"id":"paragraph-1","text":"PubMed lists PMID 38717708 in PharmacoEconomics as Journal Article, with publication-date metadata of 2024-05-08 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-38717708-2026-07-12-52000ff1efbe"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-38717708-2026-07-12-52000ff1efbe"]}],"sources":[{"id":"pubmed-observation-pmid-38717708-2026-07-12-52000ff1efbe","name":"PubMed","sourceClass":"A","title":"Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective. · retained source version 1:2026-07-12:current:52000ff1efbec556a2f29cded665122b740a254d664e7d9ab706c19f9735d7f6","url":"https://pubmed.ncbi.nlm.nih.gov/38717708/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"e9f45b527c832d743d147b964e82ba7ed977d9ce1f8cde0a70d1dd351ea955ab","tierARecordSha256":"2183ae4528c1a579a2af40b93857d8e74ffa928f3054f3a7e06653d6fcb1162f"},"integrity":{"algorithm":"sha256","contentSha256":"661f14d7b7962c98f651b60ab81f3798a833508ef459faa058346d82180f9af8"}}